The FDA has asked Eli Lilly for safety data on its weight loss pill Foundayo.
The Food and Drug Administration is asking Eli Lilly to gather more safety data on its new weight loss pill, Foundayo, ...
"Lilly debuts more Foundayo data as FDA requests post-marketing trials" was originally created and published by ...
The FDA also asked Lilly to conduct a milk-only lactation study in women who have received a dose to assess concentrations of ...
President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push to clear ...
The U.S. Food and Drug Administration (FDA) has told Eli Lilly to study possible heart, liver and other risks tied to its new ...
FDA moves shaping drug development and oversight include new gene therapy guidance, clinical trial transparency efforts, and recent drug approvals.
FDA seeks additional safety data from Eli Lilly for Foundayo to assess cardiovascular, liver, thyroid, and pediatric risks post-approval.
Some 30% of clinical trials that are mandated to report their findings have not posted results to clinicaltrials.gov, the ...
Twelve months after releasing a roadmap to shift away from animal testing requirements, the FDA has declared mission ...
Marking a fundamental shift in how we define acceptable clinical proof, it has indicated that one well-controlled trial, ...
Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results